Yaming Hang

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

Jeff Sevigny, Ping Chiao, Thierry Bussière et al. · Nature · 2016 · 3K citations

Neurodegenerative Diseases, Alzheimer's Disease, Medicine +7

Pharmacokinetics and Pharmacodynamics of Once-Daily versus Twice-Daily Raltegravir in Treatment-Naïve HIV-Infected Patients

Matthew L. Rizk, Yaming Hang, Wen‐Lin Luo et al. · Antimicrobial Agents and Chemotherapy · 2012 · 92 citations · Full text

Orexin 2 receptor‐selective agonist danavorexton (<scp>TAK</scp>‐925) promotes wakefulness in non‐human primates and healthy individuals

Rebecca Evans, Haruhide Kimura, Masato Nakashima et al. · Journal of Sleep Research · 2023 · 26 citations · Full text

Oveporexton, an Oral Orexin Receptor 2–Selective Agonist, in Narcolepsy Type 1

Yves Dauvilliers, Giuseppe Plazzi, Emmanuel Mignot et al. · New England Journal of Medicine · 2025 · 24 citations

Population Pharmacokinetics of Daclizumab High-Yield Process in Healthy Volunteers and Subjects with Multiple Sclerosis: Analysis of Phase I–III Clinical Trials

Lei Diao, Yaming Hang, Ahmed A. Othman et al. · Clinical Pharmacokinetics · 2016 · 19 citations

Therapeutic Drug Monitoring, Clinical Therapeutic, Pharmacology +8